RETATRutide (20 MG)

Marketing Description
Retatrutide is the heavy artillery of metabolic research—a next-gen triple agonist being studied for extreme, clinically significant weight loss and metabolic reset. In trials, it’s shown the ability to crush appetite, improve glycemic control, and push the body toward sustained fat burning. Researchers use it to explore what happens when you hit multiple metabolic switches at once instead of nibbling at one pathway.

How It Works
Retatrutide acts as a GLP-1, GIP, and glucagon receptor agonist. GLP-1 and GIP signaling enhance glucose-dependent insulin secretion, slow gastric emptying, and ramp up satiety in the brain. Glucagon receptor activation helps increase energy expenditure and fat oxidation, especially in liver and adipose tissue. The combined effect is a powerful shift in energy balance—less intake, more burn.

Regulatory & Research Note
Retatrutide is an investigational drug in clinical trials and is not approved by the FDA for general use. This product is supplied for research purposes only and is not for human consumption, injection, or therapeutic use.